Audrey Thorp1, Jonathan G Stine2,3,4,5. 1. Department of Medicine, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey PA, USA. 2. Division of Gastroenterology and Hepatology, Department of Medicine, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey PA, USA. 3. Department of Public Health Sciences, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey PA, USA. 4. Liver Center, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey PA, USA. 5. Cancer Institute, The Pennsylvania State University- Milton S. Hershey Medical Center, Hershey PA, USA.
Abstract
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of global liver disease. Because current pharmacologic treatments are ineffective, lifestyle change centered on exercise remains the most effective NAFLD treatment. The aim of this systematic review is to summarize and evaluate the current evidence supporting the use of exercise training as a medical treatment for adult patients with NAFLD. RECENT FINDINGS: At least 150 minutes each week of moderate intensity exercise of any type can improve NAFLD, both with and without modest weight loss. Exercise training reduces hepatic steatosis and liver inflammation, favorably changes body composition, improves vascular endothelial function, increases cardiorespiratory fitness and can lead to histologic response. To date, exercise-based NAFLD trials are limited by small sample size and significant heterogeneity. SUMMARY: While several key questions remain unanswered, exercise training will always be an important part of the medical management of patients with NAFLD.
PURPOSE OF REVIEW: Nonalcoholic fatty liver disease (NAFLD) is a leading cause of global liver disease. Because current pharmacologic treatments are ineffective, lifestyle change centered on exercise remains the most effective NAFLD treatment. The aim of this systematic review is to summarize and evaluate the current evidence supporting the use of exercise training as a medical treatment for adult patients with NAFLD. RECENT FINDINGS: At least 150 minutes each week of moderate intensity exercise of any type can improve NAFLD, both with and without modest weight loss. Exercise training reduces hepatic steatosis and liver inflammation, favorably changes body composition, improves vascular endothelial function, increases cardiorespiratory fitness and can lead to histologic response. To date, exercise-based NAFLD trials are limited by small sample size and significant heterogeneity. SUMMARY: While several key questions remain unanswered, exercise training will always be an important part of the medical management of patients with NAFLD.
Authors: Patrick Austin; Lynn Gerber; James M Paik; Jillian K Price; Carey Escheik; Zobair M Younossi Journal: J Sports Med Phys Fitness Date: 2019-02-12 Impact factor: 1.637
Authors: Catherine Properzi; Therese A O'Sullivan; Jill L Sherriff; Helena L Ching; Garry P Jeffrey; Rachel F Buckley; Jonathan Tibballs; Gerry C MacQuillan; George Garas; Leon A Adams Journal: Hepatology Date: 2018-10-14 Impact factor: 17.425
Authors: David van der Poorten; Kerry-Lee Milner; Jason Hui; Alexander Hodge; Michael I Trenell; James G Kench; Roslyn London; Tony Peduto; Donald J Chisholm; Jacob George Journal: Hepatology Date: 2008-08 Impact factor: 17.425
Authors: Mehmet Sayiner; Maria Stepanova; Huong Pham; Bashir Noor; Mercedes Walters; Zobair M Younossi Journal: BMJ Open Gastroenterol Date: 2016-08-16
Authors: Walid Kamal Abdelbasset; Sayed A Tantawy; Dalia M Kamel; Bader A Alqahtani; Tamer E Elnegamy; Gaber S Soliman; Ahmed A Ibrahim Journal: Medicine (Baltimore) Date: 2020-03 Impact factor: 1.889
Authors: Jonathan G Stine; Ian R Schreibman; Alison J Faust; Jessica Dahmus; Benjamin Stern; Christopher Soriano; Gloriany Rivas; Breianna Hummer; Scot R Kimball; Nate R Geyer; Vernon M Chinchilli; Rohit Loomba; Kathryn Schmitz; Christopher Sciamanna Journal: Hepatology Date: 2022-01-22 Impact factor: 17.298
Authors: Robert H Lustig; David Collier; Christopher Kassotis; Troy A Roepke; Min Ji Kim; Etienne Blanc; Robert Barouki; Amita Bansal; Matthew C Cave; Saurabh Chatterjee; Mahua Choudhury; Michael Gilbertson; Dominique Lagadic-Gossmann; Sarah Howard; Lars Lind; Craig R Tomlinson; Jan Vondracek; Jerrold J Heindel Journal: Biochem Pharmacol Date: 2022-04-05 Impact factor: 6.100